Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot P48023: Variant p.Cys202Ser

Tumor necrosis factor ligand superfamily member 6
Gene: FASLG
Feedback?
Variant information Variant position: help 202 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance
Residue change: help From Cysteine (C) to Serine (S) at position 202 (C202S, p.Cys202Ser). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from medium size and polar (C) to small size and polar (S) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help -1 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page
Variant description: help In ALPS1B; significant reduction in cytotoxicity and apoptosis and inhibition of the shedding of the soluble form. Any additional useful information about the variant.


Sequence information Variant position: help 202 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 281 The length of the canonical sequence.
Location on the sequence: help VINETGLYFVYSKVYFRGQS C NNLPLSHKVYMRNSKYPQDL The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences. 
Human                         VINETGLYFVYSKVYFRGQSCNNLPLSHKVYMRNSKYPQDL

Rhesus macaque                VINETGLYFVYSKVYFRGQSCTNLPLSHKVYMRNSKYPQDL

Mouse                         VINETGLYFVYSKVYFRGQSCNNQPLNHKVYMRNSKYPEDL

Rat                           VINEAGLYFVYSKVYFRGQSCNSQPLSHKVYMRNFKYPGDL

Pig                           VINDTGLYFVYSKVYFRGQYCNNQPLSHKVYTRNSRYPQDL

Cat                           VINDTGMYFVYSKVNFRGQSCNNQPLNHKVYMRNSKYPQDL
Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 1 – 281 Tumor necrosis factor ligand superfamily member 6, membrane form
Chain 130 – 281 Tumor necrosis factor ligand superfamily member 6, soluble form
Topological domain 103 – 281 Extracellular
Glycosylation 184 – 184 N-linked (GlcNAc...) asparagine
Disulfide bond 202 – 233
Alternative sequence 128 – 281 Missing. In isoform 2.
Mutagenesis 206 – 206 P -> DFR. Lowers binding to TNFRSF6 and reduces cytotoxicity more than 100-fold.
Mutagenesis 218 – 218 Y -> FR. Lowers binding to TNFRSF6 and abolishes cytotoxicity.



Literature citations
Decreased activation-induced cell death by EBV-transformed B-cells from a patient with autoimmune lymphoproliferative syndrome caused by a novel FASLG mutation.
Ruiz-Garcia R.; Mora S.; Lozano-Sanchez G.; Martinez-Lostao L.; Paz-Artal E.; Ruiz-Contreras J.; Anel A.; Gonzalez-Granado L.I.; Moreno-Perez D.; Allende L.M.;
Pediatr. Res. 78:603-608(2015)
Cited for: VARIANT ALPS1B SER-202; CHARACTERIZATION OF VARIANT ALPS1B SER-202;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.